The approval of an antidote to reverse the blood thinning effects of the anticoagulant Xarelto is expected in 2016, and it should boost sales of the drug and help prevent serious injuries and deaths from major bleeding events. Xarelto, made by Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals, was approved in 2011 to go head-to-head with the long-used warfarin in the prevention of strokes in patients with atrial fibrillation. It has since been approved to treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone hip or knee replacement surgery. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.